Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B round brings $48.2mm to Karyopharm; $19mm added

Executive Summary

Karyopharm Therapeutics Inc. (nuclear transport modulators for cancer) plans to use the $48.2mm raised through a Series B round to fund clinical trials of its KPT330, a Phase I compound for advanced, relapsed, or refractory blood and solid tumors. An undisclosed private investor led the round, and was joined by additional buyers including Delphi Ventures, which takes a seat on Karyopharm's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies